Immunotherapy Side Effects: What Nurses Should Look Out For

Article

An expert goes over the common – and not-so-common – immune-related adverse events.

Oncology nurses are usually on the forefront of handling adverse events (AEs) associated with cancer treatments. Now, as immunotherapy continues to evolve in the lung cancer treatment landscape and other malignancies, it is crucial that nurses know the dangerous AEs to look out for.

“I think general principles for any (provider) who is giving immunotherapy is to know the mechanisms of immunotherapy, and how they work in the body are different to chemotherapy. Therefore, the side effect profile that we expect to see is different,” said Jarushka Naidoo, M.B.B.Ch., an assistant professor of oncology at the Sidney Kimmel Cancer Center at Johns Hopkins University, who presented on the management of immune-related AEs at the 16th Annual Winter Lung Cancer Conference in Miami.

Immunotherapy works by activating the immune system to recognize and fight cancer cells. Checkpoint inhibitors do this by blocking certain proteins — such as PD-1 and PD-L1 – which act as a disguise for the cancer, blinding the immune system to the malignancy. But, once these checkpoints stop working, the immune cells, usually T cells, can identify and attack cancer.

Common immunotherapy agents that are being used in the lung cancer space include ipilimumab (Yervoy), an anti-CTLA-4 agent, nivolumab (Opdivo), a PD-1 inhibitor, and pembrolizumab (Keytruda), also a PD-1 inhibitor.

That being said, inflammation and flu-like symptoms are not uncommon for patients who are on immunotherapy. Most commonly, patients experience colitis, pneumonitis, and hepatitis. But Naidoo mentioned that patients and providers should also be aware of the more serious immune-related AEs, such as myocarditis and encephalitis.

“These are very rare, but they can exist,” she added.

If nurses recognize the signs of these potentially life-threatening AEs, they should act immediately — and that may mean bringing in more members to the treatment team.

“Hearteningly, (immune-related AEs) usually get better with steroid medications, but if the oncologist feels that he or she is in a realm that they’ve never seen a toxicity before, they should have a very low threshold for calling another medical oncologist or an organ specialist that may have expertise in that area.”

Related Videos
Yelena Shames
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.